A phase I and pharmacological study of amrubicin and topotecan in patients of small-cell lung cancer with relapsed or extensive-disease small-cell lung cancer

Lung Cancer

Volumn 53, Issue 2, 2006, Pages 189-195

  Shibayama, Takuo ^a   Hotta, Katsuyuki ^b   Takigawa, Nagio ^a   Tada, Atsuhiko ^a   Ueoka, Hiroshi ^b   Harita, Shingo ^c   Kiura, Katsuyuki ^b   Tabata, Masahiro ^b   Segawa, Yoshihiko ^d   Nogami, Naoyuki ^d   Kuyama, Shoichi ^c   Shinkai, Tetsu ^d   Tanimoto, Mitsune ^b  

^a Department of Internal Medicine   (Japan)

^b OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^c CHUGOKU CENTRAL HOSPITAL   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION SHIKOKU CANCER CENTER   (Japan)

Author keywords

Amrubicin; Lung cancer; Pharmacokinetics; Phase I trial; Topotecan

Indexed keywords

AMRUBICIN; DEXAMETHASONE; GRANISETRON; GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; LEUKOPENIA; LIVER TOXICITY; LUNG SMALL CELL CANCER; MALAISE; MALE; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

AGED; ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BIOLOGICAL MARKERS; CARCINOMA, SMALL CELL; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; TOPOTECAN; TREATMENT OUTCOME;

EID: 33745594550     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.05.008     Document Type: Article

References (28)

1. Noda K., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 (2002) 85-91
2. Livingston R.B., Stephens R.L., Bonnet J.D., Grozea P.N., and Lehane D.E. Long-term survival and toxicity in small cell lung cancer. Southwest Oncology Group study. Am J Med 77 (1984) 415-417
3. Johnson B.E., Ihde D.C., Bunn P.A., Becker B., Walsh T., Weinstein Z.R., et al. Patients with small-cell lung cancer treated with combination chemotherapy with or without irradiation. Data on potential cures, chronic toxicities, and late relapses after a five- to eleven-year follow-up. Ann Intern Med 103 (1985) 430-438
4. Ihde D.C., Pass H.I., and Glatstein E. Small cell lung cancer. In: De Vita Jr. V.T., Hellman S., and Rosenberg S.A. (Eds). Cancer: principles and practice of oncology. 5th ed. (1997), Lippincott-Raven, Philadelphia 911-949
5. Albain K.S., Crowley J.J., Hutchins L., Gandara D., O'Bryan R.M., Von Hoff D.D., et al. Predictors of survival following relapse or progression of small cell lung cancer. Southwest Oncology Group Study 8605 report and analysis of recurrent disease data base. Cancer 72 (1993) 1184-1191
6. Ettinger D.S. New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer. Semin Oncol 28 (2001) 27-29
7. Yana T., Negoro S., Takada Y., Yokota S., Fukuoka M., and The West Japan Lung Cancer Group. Phase II study of amrubicin (SM-5887), a 9-amino-anthracycline, in previously untreated patients with extensive stage small-cell lung cancer (ES-SCLC): A West Japan Lung Cancer Group Trial. Proc Am Soc Clin Oncol 17 (1998) 450c (abstr 1734)
8. Schiller J.H., Kim K., Hutson P., DeVore R., Glick J., Stewart J., et al. Phase II study of topotecan in patients with exensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 14 (1996) 2345-2352
9. Gupta R.S., Gupta R., Eng B., Lock R.B., Ross W.E., Hertzberg R.P., et al. Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I. Cancer Res 48 (1998) 6404-6410
10. Eng W.K., McCabe F.L., Tan K.B., Mattern M.R., Hoffman G.A., Woessner R.D., et al. Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content. Mol Pharmacol 38 (1990) 471-480
11. Sugimoto Y., Tsukahara S., Oh-hara T., Liu L.F., and Tsuruno T. Elevated expression of DNA topoisomerase II in camptothecin-resistant human tumor cell lines. Cancer Res 50 (1990) 7962-7965
12. Masuda N., Matsui K., Negoro S., Takifuji N., Takeda K., Yana T., et al. Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 16 (1998) 3329-3334
13. Mountain C.F. Revisions in the international system for staging lung cancer. Chest 111 (1997) 1710-1717
14. Negoro S., Fukuoka M., Nakamura S., Ikegami H., Sugiura T., Ariyoshi Y., et al. Phase I-II study of amrubicin (SM-5887), a novel 9-amino-antracycline, by IV administration for 3 consecutive days in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 14 (1995) 361 [Abstract 1105]
15. Kobayashi K., Hino M., Fukuoka M., Takeuchi K., Furuse K., Yoneda S., et al. Phase I studies of nogitecan hydrochloride for Japanese. Int J Clin Oncol 7 (2002) 177-186
16. Rowinsky E.K., Grochow L.B., Henricks C.B., Ettinger D.S., Forastiere A.A., Hurowitz L.A., et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. J Clin Oncol 10 (1992) 647-656
17. Shimoyama M. The Japanese edition of the National Cancer Institute-Common Toxicity Criteria (in Japanese). Gan To Kagaku Ryoho 26 (1999) 1084-1109
18. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2002) 205-216
19. Kano Y., Suzuki K., Akutsu M., Suda K., Inoue Y., Yoshida M., et al. Effects of CPT-11 in combination with other anti-cancer agents in culture. Int J Cancer 50 (1992) 604-610
20. D'Arpa P., Beardmore C., and Liu L.F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50 (1990) 6919-6924
21. Kaufmann S.H. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51 (1991) 1129-1136
22. Bertrand R., O'Connor P.M., Kerrigan D., and Pommier Y. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly glowing human colon carcinoma HT-29 cells. Eur J Cancer 28A (1992) 743-748
23. Kim R., Hirabayashi N., Nishiyama M., Jinushi K., Toge T., and Okada K. Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice. Int J Cancar 50 (1992) 760-766
24. Karato A., Sasaki Y., Shinkai T., Eguchi K., Tamura T., Ohe Y., et al. Phase I study of CPT-11 and etoposide in patiets with refractory solid tumors. J Clin Oncol 11 (1993) 2030-2035
25. Masuda N., Fukuoka M., Kudoh S., Matsui K., Kusunoki Y., Takada M., et al. Phase I and pharmacologic study of irinotecan and etoposide with recombinant human granulocyte colony-stimulating factor support for advanced lung cancer. J Clin Oncol 12 (1994) 1833-1841
26. Ohe Y., Negoro S., Matsui K., Nakagawa K., Sugiura T., Takada Y., et al. Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer. Ann Oncol 16 (2005) 430-436
27. Noguchi T., Ichii S., Morisada S., Yamaoka T., and Yanagi Y. In vivo efficacy and tumor-selective metabolism of amrubicin to its active metabolite. Jpn J Cancer Res 89 (1998) 1055-1060
28. Kubota K., Nishiwaki Y., Kakinuma R., Hojo F., Matsumoto T., Ohmatsu H., et al. Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer. J Clin Oncol 15 (1997) 292-296